Market Cap 137.01B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.08
Forward PE 8.28
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 57,957,600
Avg Vol 39,182,297
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 2%
Beta 0.34
Analysts Sell
Price Target $29.24

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
framus_morrigan
framus_morrigan Jun. 26 at 8:06 AM
$PFE $25 didn't hold. This is the QUARTERLY CHART. Soon It's about to be completed that nasty quarterly candle. The price took an eternity to reach $28 and just a blink to get back close to its long term uptrend support. Q1 gains erased in Q2, Geez ... 🙄
0 · Reply
CrispDry
CrispDry Jun. 26 at 5:30 AM
$PFE just lost another mega patent to generic. They need new management and a new vision
0 · Reply
SanKish
SanKish Jun. 26 at 5:11 AM
$ACAD nah, just check $PFE . Not all pharma is going up.
0 · Reply
umiak1
umiak1 Jun. 26 at 4:22 AM
$PFE “The $7.7 Billion Operational CushionTo directly insulate the bottom line and dividend from upcoming Loss of Exclusivity (LOE) pressures like Ibrance and Xeljanz, Pfizer is executing a massive multi-phase cost-realignment program targeting $7.7 billion in total savings through 2027: $4.5 Billion in base operational net savings completed by end-of-year 2025. $1.2 Billion in corporate SG&A reductions driven by digital automation and AI scaling through 2027. $1.5 Billion stemming from an ongoing global manufacturing optimization initiative. $500 Million via optimized R&D productivity overhauls. *Biospace This aggressive deflation of the company’s internal cost structure artificially preserves operating margins, providing a crucial cash cushion exactly as the Ibrance revenue decline begins in Q2 2027. Pfizer has aggressively rewritten its capital priority playbook to defend the payout. (AI)
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 26 at 3:08 AM
$TNXP here are some likely winners long: TNXP $PFE $IMRX $ALT I will give dozens more - plus my favorite shorts - starting July 1st 🤐
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 1:48 AM
$SLS $PFE $BMY $ABBV $MRK 5. Fast Track Designation • Indications: AML, MPM, and MM. • Details: Expedites the FDA review and development process for drugs treating serious conditions that fill unmet medical needs. 6. 3 Priority Review Vouchers worth $450 Million Dollars at current market rates for PRV’s for big pharmaceutical suitors. 7. 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL phase 3 readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth= $240.00+ after Bidding War. REGAL phase 3 Paradigm Shifting data is about to delivers perhaps the most consequential and contested acquisition in Biotechnology sector has seen in a generation. ***Change of Control filed today, all the pieces are now in place. ✌️🙏❤️‍🩹
1 · Reply
markbrogan
markbrogan Jun. 26 at 1:13 AM
$PFE this was a well coordinated and orchestrated short. The stock biunce back very soon.
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 26 at 12:07 AM
$PFE Share Price: $23.68 Contract Selected: Jul 17, 2026 $25 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.14 – $0.17 Potential Upside: 74% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
simonds
simonds Jun. 25 at 11:29 PM
$PFE Looks like the algorithms instruct buying in the morning in order to suck people into buying and then dump the large firms shares at a better price.
0 · Reply
Willieberich
Willieberich Jun. 25 at 10:54 PM
$PFE I can't sit on this twits back and forth garbage .i know what's happening here ..don't get your info on twits .pothead is a shorter hedge fund
0 · Reply
Latest News on PFE
Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 1 day ago

Pfizer Declares Third-Quarter 2026 Dividend


Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 1 day ago

Pfizer dismissed from US states' drug price-fixing lawsuit


Pfizer (PFE) Shares Sink After Surprise CFO Exit

2026-06-18T18:35:11.000Z - 7 days ago

Pfizer (PFE) Shares Sink After Surprise CFO Exit


Pfizer reaffirms all components of FY26 guidance

2026-06-18T17:30:31.000Z - 7 days ago

Pfizer reaffirms all components of FY26 guidance


Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 7 days ago

Pfizer CFO Dave Denton to step down, leave company in August


Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 7 days ago

Pfizer Announces Chief Financial Officer Transition


Pfizer says FDA approves expanded indication for Hympavzi

2026-06-08T10:51:57.000Z - 17 days ago

Pfizer says FDA approves expanded indication for Hympavzi


US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 17 days ago

US FDA approves Pfizer's bleeding disorder drug for children


Pfizer presents results from Phase 2b studies of berobenatide

2026-06-07T22:00:49.000Z - 18 days ago

Pfizer presents results from Phase 2b studies of berobenatide


Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 19 days ago

Pfizer Transcript: Study update


Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 19 days ago

Pfizer Slides: Study update


Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 19 days ago

Pfizer Press release: Study update


Mailbag: A Follow-Up on Pfizer & Other Questions

May 30, 2026, 9:22 AM EDT - 26 days ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA


Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:09 PM EDT - 7 weeks ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC


Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 4:02 PM EDT - 7 weeks ago

Pfizer CEO on AI-designed molecule, and race to use new tech


3 Dividend Stocks for May 2026

May 5, 2026, 11:30 AM EDT - 7 weeks ago

3 Dividend Stocks for May 2026

SYY WSO


Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings Call Transcript: Q1 2026


Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings release: Q1 2026


Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Quarterly report: Q1 2026


Pfizer Slides: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Slides: Q1 2026


Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 8:35 AM EDT - 7 weeks ago

Pfizer Posts Better-Than-Expected Revenue, Profit


Why selling these 3 dividend stocks could be a mistake

May 5, 2026, 7:05 AM EDT - 7 weeks ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS


US FDA approves Pfizer, Arvinas' breast cancer drug

May 1, 2026, 12:37 PM EDT - 7 weeks ago

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN


Pfizer's blood cancer drug meets main goal in late-stage trial

Apr 29, 2026, 7:42 AM EDT - 2 months ago

Pfizer's blood cancer drug meets main goal in late-stage trial


framus_morrigan
framus_morrigan Jun. 26 at 8:06 AM
$PFE $25 didn't hold. This is the QUARTERLY CHART. Soon It's about to be completed that nasty quarterly candle. The price took an eternity to reach $28 and just a blink to get back close to its long term uptrend support. Q1 gains erased in Q2, Geez ... 🙄
0 · Reply
CrispDry
CrispDry Jun. 26 at 5:30 AM
$PFE just lost another mega patent to generic. They need new management and a new vision
0 · Reply
SanKish
SanKish Jun. 26 at 5:11 AM
$ACAD nah, just check $PFE . Not all pharma is going up.
0 · Reply
umiak1
umiak1 Jun. 26 at 4:22 AM
$PFE “The $7.7 Billion Operational CushionTo directly insulate the bottom line and dividend from upcoming Loss of Exclusivity (LOE) pressures like Ibrance and Xeljanz, Pfizer is executing a massive multi-phase cost-realignment program targeting $7.7 billion in total savings through 2027: $4.5 Billion in base operational net savings completed by end-of-year 2025. $1.2 Billion in corporate SG&A reductions driven by digital automation and AI scaling through 2027. $1.5 Billion stemming from an ongoing global manufacturing optimization initiative. $500 Million via optimized R&D productivity overhauls. *Biospace This aggressive deflation of the company’s internal cost structure artificially preserves operating margins, providing a crucial cash cushion exactly as the Ibrance revenue decline begins in Q2 2027. Pfizer has aggressively rewritten its capital priority playbook to defend the payout. (AI)
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 26 at 3:08 AM
$TNXP here are some likely winners long: TNXP $PFE $IMRX $ALT I will give dozens more - plus my favorite shorts - starting July 1st 🤐
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 26 at 1:48 AM
$SLS $PFE $BMY $ABBV $MRK 5. Fast Track Designation • Indications: AML, MPM, and MM. • Details: Expedites the FDA review and development process for drugs treating serious conditions that fill unmet medical needs. 6. 3 Priority Review Vouchers worth $450 Million Dollars at current market rates for PRV’s for big pharmaceutical suitors. 7. 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL phase 3 readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth= $240.00+ after Bidding War. REGAL phase 3 Paradigm Shifting data is about to delivers perhaps the most consequential and contested acquisition in Biotechnology sector has seen in a generation. ***Change of Control filed today, all the pieces are now in place. ✌️🙏❤️‍🩹
1 · Reply
markbrogan
markbrogan Jun. 26 at 1:13 AM
$PFE this was a well coordinated and orchestrated short. The stock biunce back very soon.
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 26 at 12:07 AM
$PFE Share Price: $23.68 Contract Selected: Jul 17, 2026 $25 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.14 – $0.17 Potential Upside: 74% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
simonds
simonds Jun. 25 at 11:29 PM
$PFE Looks like the algorithms instruct buying in the morning in order to suck people into buying and then dump the large firms shares at a better price.
0 · Reply
Willieberich
Willieberich Jun. 25 at 10:54 PM
$PFE I can't sit on this twits back and forth garbage .i know what's happening here ..don't get your info on twits .pothead is a shorter hedge fund
0 · Reply
Willieberich
Willieberich Jun. 25 at 10:51 PM
$PFE someone let pothead I'm still here! I will be buying as this goes down small at 1st .but holding some of my position .good luck people .
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 25 at 10:46 PM
$PFE read the ex divy date wrong today and rolled my puts I sold for the wrong price 🫩
1 · Reply
MrPeanutEsquire
MrPeanutEsquire Jun. 25 at 10:06 PM
$PFE So far its really only failed people who's immune systems were already shot to hell with chemo. Im siding more with the optimism from Pfizer. It was given as a hail Mary last ditch effort and couldn't pull a miracle but that doesn't mean it cant do what its designed to do and so far we dont have those results. Would have been great if it could have worked magic on those people but it sounds like Pfizer never really expected it to. It was just a long shot hope and you might as well give it a try. Am I off base here?
0 · Reply
Woodmont
Woodmont Jun. 25 at 10:04 PM
$PFE Most major pharmaceutical companies companies share price has risen between 10-40% in the last year, LLY, JNJ, BIIB, JAZZ, MRK you get the point and yet this crap has gone nowhere but down, that should tell us something number one the street hates current management, number 2 they should be buying back shares cut the divy and use the money to buy back shares, the current CEO tells us nothing about what he is doing to improve shareholder value he has said nothing, he must go bring in someone with some vision
1 · Reply
simonds
simonds Jun. 25 at 9:57 PM
$PFE Borla is simply not qualified to be ceo. He is a veterinarian who does not have the proper experience running a large pharma company. This fiasco should be more on the board of directors for hiring him and continue to let him run this once quality company into the ground. Bourla is in way over his head.
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jun. 25 at 9:50 PM
$PFE After the results, artificial intelligence gives SV a 35% chance of still being a blockbuster. Thats not too bad I guess
1 · Reply
simonds
simonds Jun. 25 at 9:46 PM
$PFE Loser management, including the board of directors
0 · Reply
simonds
simonds Jun. 25 at 9:45 PM
$PFE Management Stinks, they overpay for useless companies; they make very poor decisions in all aspects of running a pharma company.
0 · Reply
Mexu
Mexu Jun. 25 at 9:35 PM
$PFE Denton was headhunted from Pfizer. However, he can’t save Nike as Nike needs trendsetter, not a finance guy
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Jun. 25 at 9:30 PM
$PFE - Oh yeah, Pfizer, the pharma ‘giant’
1 · Reply
simonds
simonds Jun. 25 at 9:30 PM
$PFE Charlie represents the shareholders, Lucy represents Borla and the board of directors.
0 · Reply
ItsCarRamRod
ItsCarRamRod Jun. 25 at 9:22 PM
$PFE so come back around the year 2029 and bourla will make a difference, ROFL.
0 · Reply